dow component visa aig and gilead. expert animal cyst fromalysis from the pros. >>> later, manny pacqaoi talks up his fight against floyd mayweather this las vegas. the pacman stands to take home more than $100 million. what if there were only one kind of dog? then it would be easy to know everything about that one breed. but in fact, there are over three hundred breeds of dogs. because no one can be an expert in every one... an app powered by ibm watson will help vets tap specialized knowledge in the cloud for every breed... and whatever else walks, flies or slithers through the door. ibm watson is working to make medicine smarter every day. ♪ ♪ (ee-e-e-oh-mum-oh-weh) (hush my darling...) (don't fear my darling...) (the lion sleeps tonight.) (hush my darling...) man snoring (don't fear my darling...) (the lion sleeps tonight.) woman snoring take the roar out of snore. yet another innovation only at a sleep number store. >>> welcome back. we've got 45 minutes left in the trading session. the selling intensifies here. t

you look at gilead and they crushed. so to me it's the etf taking down the individual stocks but that can last a lot longer that i want it to. >> i agree on the biotech. it really was indiscriminant selling and felt very panicky. if you look at the apple move it's a decent size move since the earnings but it did not seem panicky to me at all. maybe there's more downside, maybe there's more to get fleshed out. i don't know if these etf flows -- i don't know if they move differently than the underlying stocks. it sounds like you think that they do. then i think there's probably a little more to go. i'm long. this is clearly a painful couple of days, week. but i'm going to stay long. it's been a multiyear trade. i'm going to stay in it. >> let's follow inup in terms of the etf. there was a lot of generals that got into the space. do you agree with karen in that you think that the selling will continue? >> i do actually. part of the reason is of course that there are just so many shorts in these names, even in this etf, this

i just want to find out about gilead and what's going on with gilead this week. >> it's got a problem. it's a high quality problem if i don't say so myself. it has too much cash. it has to make an acquisition. it has to make something that makes people feel like don't worry if there's too much competition. i am a fan of gilead as i am a fan of regeneron and biogen as they are the four horse men that i wrote about. greg in new york. greg greg. >> good evening. i'm trying to find out what's wrong with alcoa. >> people are concerned about the price of aluminum. people feel that alcoa is going to be hurt by chinese dumping. i don't think they're going to dump. i think they need it. it changed the equation. i'm viewing alcoa where it will be six months to a year from now. therefore i think i said it it's a buy. dick in virginia. >> hi a great big booyah. congratulations on your wedding and health and long life to you. >> thank you, same. >> their earnings are decelebrating and and it's rather high. they're going to nail it. and the second is gilead's earnings are due out next week. i wonde

gilead science is up. scarlet, what do you have?they are declaring their first cash dividend. profits beat analyst estimates $2.60 for the adjusted -- you know what? i have a new number. $2.94, where the consensus was $2.32. the first quarter revenue as well, topping the consensus. $7.9 billion. analysts were expecting something shy of $6.9 billion. all of this after the gilead blockbuster hepatitis drug. there has been a lot of concern about the sale profits there. nevertheless, the sales 970 $2 million. that does appear to be shy of the consensus element of $2.4 billion. the hepatitis c drug again that gilead science has put out a breakthrough lock buster drug for the company. company is raising its net product forecast. alix: all right, thanks so much, scarlet. cory johnson joins us in san francisco. break it down for us. cory: yes, the stock is cratering. getting quite a haircut -- get it, alix? you look great. linkedin numbers, the guidance, i think is like here for the fourth quarter and for the year. but that said, their busi

shares of vertex and gilead.d buy vertex mylan up 8%. >>> the coming up bill nye the science guy has a new venture, teaming up with sylvan learning to get kids into robotics and he's live here at post 9 to explain. the promise of the cloud is that every organization has unlimited access to information, no matter where they are. the microsoft cloud gives our team the power to instantly deliver critical information to people, whenever they need it. here at accuweather we get up to 10 billion data requests every day. the cloud allows us to scale up so we can handle that volume. we can help keep people safe and to us that feels really good. why do we do it? why do we spend every waking moment, thinking about people? why are we so committed to keeping you connected? why combine performance with a conscience? why innovate for a future without accidents? why do any of it? why do all of it? because if it matters to you it's everything to us. the xc60 crossover. from volvo. lease the well equiped volvo xc60 today. visit y

first day of may in have investors go away in steve, to you on gilead, they had an amazing earning perioding up, it is up like a buck. this stock in my mine should be up to 20 dollars. are biotechs destined to get hit? >> i don't know it company well, i don't top -- don't want to speak to it specifically but this tell me that biotech is too crowded. i don't like things that heal you like now, i like things that get you sick like tobacco and alcohol. charles: all right, hillary. social media, linked in, looks like the latest victim. >> the guidance is so poor, they had to come down for second quarter. you have companies like yelp, and internet in general getting crushed. charles: you have 3 theft million member -- 350 million members, that is not enough for wall street, down she goes. >> i love fireeye, they raise guidance, and big. they are still losing money but earnings are up big. charles: the stock on cusp of perhap a break out. >> you have to watch for stocks with my multiples, you have an environment where earnings particulars are lowered, a belief that fed is raising rates. high mu

am gen, biogen, gilead. those are highly understood.ery well covered, excellent growth the last four years. good prospects for growth. everybody knows what the value should be or could be. there is no sense of talking about a bubble in that instance. you've got another 15 companies, 5 to 50 billion market cap zone. alexian, regeneron, vertex, very good companies. mostly product stories, mostly revenue-driven. none eps driven, but very well-covered, very well understood. maybe there is some optimism, we're in a generally optimistic environment as far as equities are concerned. but again, i cannot see a bubble there. the next group is what i find more interesting, a company collective 200. it's about 200 stocks going public as far back as 1980 that don't -- people don't seem to care about them. they're in a show-me category. they have disappointed so many times, so often, so significantly, that they need to show that much more than anybody else to get anybody's attention. once in a while, they'll do something, they'll get people's attenti

why sill gilead here? why? >> at this multiple which comes back to it for you. >> ten times.else to fall back on. >> and it's just not bad, versus when general electric and cisco and microsoft in 2000 were trading at unsustainable multiples. >> cisco's discount. >> in 20 on 0. cisco is a discount to the multiple. >> and we talked about google last week of course after those strong numbers. that market performance that we saw from google and amazon whoa. >> talking multiples there, i'm not in the same conversation anymore. >> but google is. >> 17 times earnings a discount to the s&p, with that balance sheet? with that level of growth? inconceivable to me how that stock can't go higher. >> in this town it's all about private market values. there, there may be at least an argument to be made guys there's more of a bubble. >> i'm examining a lot of stocks this week on "mad money" that are private. i have 40 billion there, 40 billion that. >> i would 40 billion if uber. >> 41. >> travis is no the a seller of a single share. >> abnb -- air bnb. do you think therefore they can't get

another winner, gilead again. those earnings are slowing. they're getting more competition.gen, they said trials of their drug are showing positive results. then we have intuitive pharmaceutical. they make shoulder devices. and they're most cost-effective than lapry scopic. >> what about the weak sectors? what should people be ready to see misses on? >> you'll have to look at energy. energy is the weakest sector we're looking for. profits are down 60%. if you take energy out, s&p 500 growth will be up 7%. that negative figure i gave, w we would be up 7%. >> give me a sense of the two names, i'll just pull that out, the two names that really have the power to put a leash on the market and either yank it backyards or backwards r pull it forwards. >> apple and amazon. they're the biggest by market cap. the most heavily weighted. apple adds one to 2% to the index just because how well they've reported. because of their size. exxon that will be a tricky one. oil is not expected to do well. as you said, the estimates have come so far down, it's possible they could still be. pop to

we will larry from gilead this week. i think david is right. there is this ground swell wait a second when you buy horizon, they buy drugs that are not doing well and then suddenly they raise the price. they also have a better sales force and the numbers explode on drugs that cost much less and i think that article presumed the backlash. there will be no backlash. yoke this is smart enough to catch on. >> you do not? >> no i do not. valiant lives. slashes r&d, raises prices basically is the airline of drug companies. >> ford here first quarter profit 23 cents below wall street estimates. revenue also shy of consensus the stronger dollar impact sales t. commentary from shanks on south america, jim, in his words, the external environment in south america has deteriorated to where we were a few months ago. >> that number in south america, that has been by the way a terrific line item for some of these guys. it does appear south america is in major turmoil. you will hear that from whirl poly. it does a gigantic result of it. the currencies are weak

bead leader biotechs alexion, up 2%, gilead honorable mention, up as well.outpacing the market. simon, ibb, etf that tracks it, up 2% or more today as well. >> interesting. >>> let's send it over to rick santelli in chicago for the morning's exchange. rickster? >> thank you, simon. i like to welcome our guest this tuesday, lewis woodhill thanks for tyking the time. >> good to be with you. >> listen we have a real lack of productivity we're 6 1/2 years into zerp the fed has, of course discontinued quantitative easing and we see unemployment rate closer to 5%. how do we reconcile all of that? why isn't the economy doing better and is fed policy a problem or is it just it's the wrong medicine? your thoughts? >> the fed policy isn't just a problem, it's the problem right now. the fed has let the value of the dollar rise when it should have kept it stable. the real unemployment rate last month was -- went up from 9.8% to 9.9% adjusted for labor force participation. >> all right. well let's just stick real quickly with the labor force. you know when the administra

in the value area, we like gilead. it is still doing well. liz: had a great run-up. >> it has.ed down quite a bit. on the back of good revenue and good earnings with some blockbuster drugs, we think it has potential to move higher. one of the names we really like, one of the sectors we think has the best value fundamentals, is oil. so we like halliburton. we like halliburton because it has a dividend. there are really big player in that area. liz: up 1.6%? >> yeah. we do think that the dividend is about 1.6%. the move in oil probabilities it will move higher you unless there is unknown shock to supply. liz: folks, it may feel weird, but you have got to buy lower rather than higher. what is your third name right now? >> the third name is c.r. bard which is another health care play. the health care has done really well. liz: this is medical technology, right? >> yes. but in a bear market trend you typically will move to health care. people still get sick. they need to continue to spend money to get well. and that helps the health care industry. liz: we five minutes before this cl

so it's very heavily in celgene, gilead, what we're calling blew chip. the more speculative money is. it's taking much more of a beating and tends to be a lot more volatile on the downside. you look at the probable cause of today's selloff, it's a company called celledon. it missed a phase two trial or a milestone of some sort. that's the wake-up call for this -- >> that's a $320 million plus market cap -- >> right. >> that's the point you're making is that it's small. i'm just pointing out -- >> you get away from biogen -- this is the true face of the sector. it's tremendous gains when you hit it and it's huge vegas-like losses when you miss. >> because these are true biotechs. they're not the biotechs that trade like pharma. it's all about what you have in the pipeline. if you've got it, it will fly to the upside. if not, you'll see days like this. >> celladon is down 66% from the ipo priced to its lowest point ever. just putting a -- >> it's a tough day. now tomorrow they'll start coming out with takeover rumors and -- >> 50% of all russell 2000 biote

the second is gilead. this is another one the street is a little too conservative.e know they tend beat. their profits have grown triple digits the last several quarters, slowing down though, only expected to grow 77% this quarter, a lot of competition in the hep c market. >> amazon another one, they like stopped their losing streak in the latest quarter. we expect that to continue, taking everything on from the traditional i.t. companies by offering cloud storage, streaming music, they're offering their alternative to pandora and spotify so that's one we like as well. and then i would look at another health care company, intuitive surgical, their robotics system that is more cost effective than laparoscopic that they've cornered the market on. and then the last one whirlpool. household durables in general expected to be up 20%. housing data has been mixed but we see consumers buying larger ticket items now and whirlpool is one name. >> one last look at the wall, so you can see who is coming out next week. far beyond the companies that i mentioned and even far beyon

names to watch expedia gilead and dreamworks. . stuart: let's get right to your money and bring in d.r. barton from wilmington delaware. i got two stocks start with apple. they've got problems with apple watch production. would you buy apple stock at 127 this morning? >> long-term, stuart, i am a buyer of apple. right now i would advise people against buying apple because i think just like back in 2012 when they announced the iphone 5 it spiked to all-time high and sold off for the rest of the year. we're in a similar technical situation here. two superior earnings quarters have blown it right up. made a new all-time high on tuesday for about 10 minutes and fallen off since then, fallen through a key support level. i think we've got 6-12% more downside for apple from here. so it will set up a good buying opportunity but today, not a buyer. stuart: buy it at say 115. move onto tesla. big announcement supposedly battery technology. the stock's around 220. would you buy it? >> no i'm a seller of this one. maybe in the morning is the b

and that may be true if you only have a business plan and no earnings but certainly companies like gileady solid earnings growth great innovation we think represent good value. >> just a quick question on the consumer discretionary picks you have, the sector is benefitting from lower gas prices but isn't that priced into a lot of the stocks? they had a massive run so far this year. >> there's no doubt that they're not cheap. we think they're fairly valued. not overly extended if you look at the premiums on a price to earnings basis. the relative ratio is the s&p 500. they're above average levels. the earning momentum and business profiles and respected earnings growth still remain very solid. we think they'll continue to do well and move in line with earnings growth. >> you listed quite a few sectors that you do like in this market. if we just cut out energy you're basically pretty positive on all the other sectors. >> you always want to be selective within the sectors that you like. we're not making huge top down calls here. we just find from a bottom up standpoint that the sectors i hig

you take a look at a company like gilead that made a key acquisition for $11 billion a couple of years that time investor was like why are you spending so much money on this smaller company but now hepatitis c is such a big part of their growth portfolio. for some companies acquisitions paid a big part. >> also other drugs as well. >> generics. >> twitter. >> love it. >> twitter. >> i thought you were going to say tweet us. >> i was going to say you already said that a couple of times now. no, i'm prompting you. >> a lead in. twitter reports earnings today after the bell. analysts are expecting an increase in earnings from the previous year. the big focus will be on mobile ad revenue shares and they're up nearly 45% year to date. >> on top of that we'll be talking about dupont because it faces off with a well-known activist investor ahead of the company's annual meeting. the latest on the battle for control of the board straight ahead. you're watching worldwide exchange. you can find us on twitter or on e-mail. go online. you'll figure it out. >>> hi everybody. welcome back to worldwid

all the hepc hype surrounding gilead. credit suisse -- and -- >> all right.lk" on this monday. let's move on to our new segment "trading nation." great day for gold by the way. the previous metal -- it's not a previous metal. it's a precious metal. up more than 1 prz. i have been off for a week. that means gold is beating the s&p 500 this year. let's bring in our trading nation crew. >> i'm wearing my bullish cuff links. >> solid gold? >> preparation for this segment. >> are they solid gold? >> no they happen to be silver and silver actually outperformed gold today. we're up more than 1.5%. gold is up 1.5% which is about a seven-week high. by the way want to say hi to bob pasani and i want to say hi to swraky deangeles who i see on the floor of the exchange. i have been a floor trader for 35 years. in the gold i see jackie occasionally. make a long story short, we're up because the poor jobs report woke up the funds. for the last quarter we were losing open interest in gold. we were down from say, february first week of 425,000 in round numbers to today's, th

heading into q-1 earnings we think gilead and on down the list are well positioned to continue to post cases 30% year on year growth. you can't find that anywhere else in the marketplace right now and relative to the multiples we think the earnings driven names are still attractive. >> a potential interest rate coming. volatility rising and growth slowing down in some part of the world. this isn't the best set up for bio tech which we know tends to out perform when the macro picture is intact. >> i would agree bio tech tends to be high beta. if there's an overall correction in the equity's market that would hurt the industry for sure but what we seem to be seeing is a sluggish economic environment and as you know drugs and biotech products are very economically resistant. recession resistant so right now at least we have a best possible world where biotech companies are able to pen fit from an aging population. a very open pricing environment. obamacare extended reimbursement to a broader number of people. yet there aren't any other industries capable of hosting that growth. >> so eric

when gilead reports it will be exceptional. regeneron will be exceptional.n alzheimer's story. be careful, celgene, it can still come in. other drugs i expect to kind of take the place of revelen some day. some people think the patent is not as good as it is. i like celgene but not at this price. >> we'll watch celgene. down about 3%. we've got the opening bell coming up about 6 1/2, six minutes from now. female announcer: sleep train's interest free for 3 event! ends sunday. it's your last chance to get three years interest-free financing on beautyrest black, stearns & foster serta icomfort even tempur-pedic. plus, get free delivery, and sleep train's 100-day low price guarantee. but hurry! sleep train's interest free for 3 event ends sunday. ...guaranteed! ♪ sleep train ♪ ♪ your ticket to a better night's sleep ♪ >>> you are watching "squawk on the street" on cnbc. so much goes on as we close out the month of april. a bunch of data out of europe. german retail sales were above expectations. spanish gdp best since '08. >> makes we want to sell the dollar an

these days revenues if you're talking about a gilead or a cellgen.ou had companies get back and you had big survivors like the amgens of the world. biotech might be in a mini bubble right now but there's no public participation which is the other factor that's largely been missing in the move upward. >> we were talking about that earlier. thanks to ron insana and jack moore. just about 20 minutes to go before the closing bell. dow jones industrial average off of its highs, s&p 500, 2,117.94. that's good enough for a closing high. can we close the markets now, kelly, please? >> bob. >> up next the knockoff of the apple watch. there they are turning up in china for a few months already. we have the real thing for you. we'll also have a fake. find out if you can tell the difference when we come back. (vo) me? i don't just wait for a moment. i watch for the perfect moment. the one nobody else sees. and when i find it- i go for it. (announcer) at scottrade, we share your passion for trading. that's why we give you the edge, with innovative charting and tr

you guys have tried to negotiate with gilead and others to bring these down.ure can we expect from you across the industry to push drug prices lower? >> well, i think it's less about pushing drug prices ss lower and making sure what they're spending on drugs is for the benefit of our member our customers. i think for the hepc drugs that is in the value, in the long run getting hep c cured is what we want. over time as we change the way we pay for health care individual prices of individual units used during the health care process won't be as alarming or as difficult to deal with. so we have to get to a very different payment model if we're ever going to solve this model. >> wait a minute. i'm thinking of the valeant story. you know when they bought a company, they got two drugs in the deal and they immediately raised the prices by 500% in one case, 200% in another case because they said those drugs were undervalued. what is an undervalued drug if it's effective and people are paying a price they can afford? isn't that working? i mean how do you define underva

gilead sciences and rally automotive up about 4,500%. eight incredible moves there. why don't we then head to the nasdaq and find out the big moves today with bertha coombs. >> mandy, they say history doesn't repeat but it rhymes. and this week big cap tech reasserting itself and certainly, yesterday, was the big juggernaut. if you take a look the nasdaq composite is up above 5,000 for the fifth straight day. fourth straight day of gains. but it's the nasdaq 100 that's really moving forward here up more than 4% for the week, powered by those big cap tech earnings. amazon is the big move. amazon having its best weekly gain since back in 1999 on the heels of that astonishing number and just how big its cloud business is. we have seen the cloud and amazon has a huge piece of it. its market cap today, topping $208 billion. it's going to make it a bigger lifter now within the nasdaq 100. the other heavy lifters today, microsoft. the old name huge name for microsoft on the back of that cloud break that the street seems to like as well. also google more discipline in its sp

they then renegotiated contracts with gilead in december that did not account for the better discount a bit of the upside on the margins is from exchanging and a bit from hep c. >> you like the stock? >> i like the stock. it's a value name i think. i have a $125 price target. >> all right. thank you for joining us. >> thanks becky. >> okay. coming up, baby bust. why millennials aren't having children. how the drop may signal a historic shift. first as we head to a break, s&p 500 winners and losers. we're back in just a moment. can it make a dentist appointment when my teeth are ready? ♪ ♪ can it tell the doctor how long you have to wear this thing? ♪ ♪ can it tell the flight attendant to please not wake me this time? ♪ ♪ the answer is yes, it can. so, the question your customers are really asking is can your business deliver? e financial noise financial noise financial noise financial noise >>> we're in the chairs this morning. we're playing this song because we have a problem with babies. there's not enough babies being born. there's not enough action if you will among millennials. w